40 results
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
28 Mar 24
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
8:00am
Medicines and Healthcare Products Regulatory Agency to conduct a Phase 2a human challenge study.
In December 2023 we began treating influenza-infected
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
6 Dec 23
Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A
8:00am
treatments for patients that also provide significant cost savings to the global healthcare system.”
About CC-42344
In late 2022 Cocrystal reported … received authorization from the United Kingdom Medicines and Healthcare Products Regulatory Agency to initiate a Phase 2a human challenge trial with CC
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
13 Nov 23
Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
8:15am
.
In October 2023 we announced authorization from the United Kingdom Medicines and Healthcare Products Regulatory Agency to conduct a Phase 2a human
8-K
EX-99.1
x3k wkytk2hx
31 Oct 23
Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344
8:00am
8-K
EX-99.1
5w96z0cl122
16 Aug 23
Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
4:05pm
8-K
EX-99.1
fclbltpppd
15 May 23
Cocrystal Pharma Reports First Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
8:00am
8-K
EX-99.1
aes6kfvritopc
26 Oct 22
Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344
8:00am
DEFA14A
70q31lx7
28 May 21
Additional proxy soliciting materials
8:10am
8-K
EX-99.1
splc2v
28 May 21
Cocrystal Pharma Announces the Passing of Chairman, CEO and Co-founder Dr. Gary Wilcox
8:05am
8-K
9nc4ejm1wbl2w8
28 May 21
Cocrystal Pharma Announces the Passing of Chairman, CEO and Co-founder Dr. Gary Wilcox
8:05am
8-K
EX-1.1
15yddi
2 Jul 20
Entry into a Material Definitive Agreement
9:30am
8-K
EX-10.1
1ews7anp muc
13 Mar 20
Cocrystal Pharma Announces Closing of $6.8 Million Registered Direct Offering Priced At-the-Market
4:44pm
8-K
EX-10.1
p9l3gdvouzq0nkob
4 Mar 20
Cocrystal Pharma Announces Closing of $11.0 Million Registered Direct Offering Priced At-the-Market
5:09pm
8-K
EX-10.1
h13 vwbzwyjd41rqr01x
31 Jan 20
Entry into a Material Definitive Agreement
8:01am